BASi to Participate in H.C. Wainright Investment Conference

Rhea-AI Summary

Bioanalytical Systems, Inc. (NASDAQ:BASI), operating as Inotiv, will participate in the H.C. Wainright 22nd Annual Global Investment Conference on September 16, 2020, at 2:30 p.m. EDT. A live webcast of the presentation will be accessible on the Investors section of the company's website and will remain available for approximately 90 days. BASi specializes in providing contract research services to pharmaceutical companies, aiming to enhance drug development efficiency and lower costs.

WEST LAFAYETTE, Ind., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We” or “Our”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced that it will participate in the H.C. Wainright 22nd Annual Global Investment Conference. The Company will present on Wednesday, September 16th, at 2:30 p.m. EDT.

A live webcast of the presentation will be available through a link that will be posted on the Investors section of the Company’s website at ir.inotivco.com and will be available for approximately 90 days.

About Bioanalytical Systems, Inc., operating as Inotiv

BASi, operating as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. BASi’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com for more information about BASi, operating as Inotiv.

This press release contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect the Company’s business and financial results are included in the Company’s filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company’s Forms 10-K, 10-Q and 8-K.

FOR MORE INFORMATION:	Company Contact:
	Beth A. Taylor
	Chief Financial Officer
	Phone: 765.497.8381
	btaylor@inotivco.com

FAQ

When will BASI participate in the H.C. Wainright Conference?

Bioanalytical Systems, Inc. (BASI) will participate in the H.C. Wainright 22nd Annual Global Investment Conference on September 16, 2020, at 2:30 p.m. EDT.

Where can I watch the BASI conference presentation?

The live webcast of the Bioanalytical Systems (BASI) presentation can be viewed on the Investors section of their website.

How long will the BASI conference presentation be available for viewing?

The webcast of the Bioanalytical Systems (BASI) presentation will be available for approximately 90 days after the event.

What services does BASI offer?

Bioanalytical Systems, Inc. (BASI) provides contract research services to emerging pharmaceutical companies and leads in drug development, focusing on efficiency and cost reduction.

What is the focus of Bioanalytical Systems, Inc. (BASI)?

BASI focuses on developing innovative services that support clients' drug discovery and development goals for improved decision-making.